Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Anika Mann"'
Autor:
Pooja Dasgupta, Anika Mann, Willma E. Polgar, Rainer K. Reinscheid, Nurulain T. Zaveri, Stefan Schulz
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract Multi-receptor targeting has been proposed as a promising strategy for the development of opioid analgesics with fewer side effects. Cebranopadol and AT-121 are prototypical bifunctional ligands targeting the nociceptin/orphanin FQ peptide r
Externí odkaz:
https://doaj.org/article/d9bd7e74763c49baa260dbab828e0fd3
Autor:
Anika Mann, Alastair C. Keen, Hanka Mark, Pooja Dasgupta, Jonathan A. Javitch, Meritxell Canals, Stefan Schulz, J. Robert Lane
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
Abstract The dopamine D2 receptor (D2R) is the target of drugs used to treat the symptoms of Parkinson’s disease and schizophrenia. The D2R is regulated through its interaction with and phosphorylation by G protein receptor kinases (GRKs) and inter
Externí odkaz:
https://doaj.org/article/ca749480bcc9489bb045eb4ed1f42bf3
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-20 (2020)
Abstract The δ-opioid receptor (DOP) is an attractive pharmacological target due to its potent analgesic, anxiolytic and anti-depressant activity in chronic pain models. However, some but not all selective DOP agonists also produce severe adverse ef
Externí odkaz:
https://doaj.org/article/7a9660019a0841789184816179841e8c
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39458 (2012)
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles. However, their ability to activate individual somatostatin receptor
Externí odkaz:
https://doaj.org/article/72b018b5770648bb9ef6b75bb471d9b2
Autor:
Anika Mann, Hanka Mark, Alastair C. Keen, J. Robert Lane, Stefan Schulz, Pooja Dasgupta, Jonathan A. Javitch, Meritxell Canals
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-17 (2021)
The dopamine D2 receptor (D2R) is the target of drugs used to treat the symptoms of Parkinson’s disease and schizophrenia. The D2R is regulated through its interaction with and phosphorylation by G protein receptor kinases (GRKs) and interaction wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2797f88d9daed5cce550cb4cef0e26c
Autor:
Pooja, Dasgupta, Anika, Mann, Willma E, Polgar, Rainer K, Reinscheid, Nurulain T, Zaveri, Stefan, Schulz
Publikováno v:
Scientific reports. 12(1)
Multi-receptor targeting has been proposed as a promising strategy for the development of opioid analgesics with fewer side effects. Cebranopadol and AT-121 are prototypical bifunctional ligands targeting the nociceptin/orphanin FQ peptide receptor (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::de196756097ee722332c05053cc3f3ab
https://pubmed.ncbi.nlm.nih.gov/35504962
https://pubmed.ncbi.nlm.nih.gov/35504962
Autor:
Anika, Mann, Alastair C, Keen, Hanka, Mark, Pooja, Dasgupta, Jonathan A, Javitch, Meritxell, Canals, Stefan, Schulz, J, Robert Lane
Publikováno v:
Scientific Reports
The dopamine D2 receptor (D2R) is the target of drugs used to treat the symptoms of Parkinson’s disease and schizophrenia. The D2R is regulated through its interaction with and phosphorylation by G protein receptor kinases (GRKs) and interaction wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::41fa9615f8af87293d0984e42d7ebb2d
https://pubmed.ncbi.nlm.nih.gov/33859231
https://pubmed.ncbi.nlm.nih.gov/33859231
Publikováno v:
Mol Pharmacol
Agonists at the nociceptin opioid peptide receptor (NOP) are under investigation as therapeutics for nonaddicting analgesia, opioid use disorder, Parkinson’s disease, and other indications. NOP full and partial agonists have both been of interest,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bfcd9b04b983918601d65f83754cae
https://pubmed.ncbi.nlm.nih.gov/33958480
https://pubmed.ncbi.nlm.nih.gov/33958480
Autor:
Andrea Kliewer, Pooja Dasgupta, Stefan Schulz, Sebastian Fritzwanker, Anika Mann, Elke Miess, Thomas Günther, Ralph Steinborn
Publikováno v:
British Journal of Pharmacology. 175:2857-2868
Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the developmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ca4ae2d37d5b491e579d26475f1f19c
https://doi.org/10.1111/bph.13809
https://doi.org/10.1111/bph.13809
Publikováno v:
Human Cell. 30:267-278
HepaRG cells are widely used as an in vitro model to assess drug-induced hepatotoxicity. However, only few studies exist so far regarding their suitability to detect the effects of drugs requiring a preceding activation via the cytochrome P450 (CYP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c055cfb76c993c84483bf7b3431f1346
https://doi.org/10.1007/s13577-017-0175-9
https://doi.org/10.1007/s13577-017-0175-9